Dr. Manish Shah, MD
Claim this profileWeill Cornell Medical College
Studies Esophageal Cancer
Studies Adenocarcinoma
13 reported clinical trials
28 drugs studied
Area of expertise
1Esophageal Cancer
Stage IV
advanced
metastatic
2Adenocarcinoma
Stage IV
advanced
metastatic
Affiliated Hospitals
Clinical Trials Manish Shah, MD is currently running
Chemotherapy + Immunotherapy
for Esophageal and Gastric Cancer
This phase III trial compares the effect of modified fluorouracil, leucovorin calcium, oxaliplatin, and irinotecan (mFOLFIRINOX) to modified fluorouracil, leucovorin calcium, and oxaliplatin (mFOLFOX) for the treatment of advanced, unresectable, or metastatic HER2 negative esophageal, gastroesophageal junction, and gastric adenocarcinoma. The usual approach for patients is treatment with FOLFOX chemotherapy. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Fluorouracil stops cells from making DNA and it may kill tumor cells. Leucovorin is used with fluorouracil to enhance the effects of the drug. Oxaliplatin works by killing, stopping, or slowing the growth of tumor cells. Some patients also receive an immunotherapy drug, nivolumab, in addition to FOLFOX chemotherapy. Immunotherapy may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Irinotecan blocks certain enzymes needed for cell division and DNA repair, and it may kill tumor cells. Adding irinotecan to the FOLFOX regimen could shrink the cancer and extend the life of patients with advanced gastroesophageal cancers.
Recruiting2 awards Phase 32 criteria
Nous-209 Vaccine
for Metastatic Cancer
Ref: Protocol v9.0, dated 7Nov2023. NOUS-209-01 is a multicenter, open-label, multiple cohorts, clinical study, designed to evaluate safety, tolerability, and immunogenicity, and to detect any preliminary evidence of anti-tumor activity of Nous-209 genetic polyvalent vaccine plus pembrolizumab combination therapy in adult subjects with unresectable or metastatic deficient mismatch repair (dMMR) or MSI-H CRC, gastric, or gastro-esophageal junction (G-E junction) tumors. Nous-209 is based on a heterologous prime/boost regimen composed of the Great Ape Adenovirus GAd20-209-FSP used for priming and Modified Vaccinia virus Ankara MVA-209-FSP used for boosting. The Phase I portion of the study is a first-in-human (FIH) clinical study with a primary objective to elucidate the safety and tolerability of Nous-209 in addition to establishing the recommended Phase 2 dose (RP2D), whereas the Phase II was introduced to assess efficacy as the primary objective.
Recruiting1 award Phase 1 & 225 criteria
More about Manish Shah, MD
Clinical Trial Related7 years of experience running clinical trials · Led 13 trials as a Principal Investigator · 5 Active Clinical TrialsTreatments Manish Shah, MD has experience with
- Nivolumab
- Pembrolizumab
- Telomelysin (OBP-301)
- ATP128
- BI 754091
- VSV-GP128
Breakdown of trials Manish Shah, MD has run
Esophageal Cancer
Adenocarcinoma
Colorectal Cancer
Gastroesophageal Junction Adenocarcinoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Manish Shah, MD specialize in?
Manish Shah, MD focuses on Esophageal Cancer and Adenocarcinoma. In particular, much of their work with Esophageal Cancer has involved Stage IV patients, or patients who are advanced.
Is Manish Shah, MD currently recruiting for clinical trials?
Yes, Manish Shah, MD is currently recruiting for 5 clinical trials in New York New York. If you're interested in participating, you should apply.
Are there any treatments that Manish Shah, MD has studied deeply?
Yes, Manish Shah, MD has studied treatments such as Nivolumab, Pembrolizumab, Telomelysin (OBP-301).
What is the best way to schedule an appointment with Manish Shah, MD?
Apply for one of the trials that Manish Shah, MD is conducting.
What is the office address of Manish Shah, MD?
The office of Manish Shah, MD is located at: Weill Cornell Medical College, New York, New York 10021 United States. This is the address for their practice at the Weill Cornell Medical College.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.